The Cigna Group CI

Morningstar Rating
Add To Portfolio
|%
Chart Data Not Available
  • Last Close
  • Sector
  • Industry
  • Investment Style
    Large Value
  • Market Cap
  • Forward Div Yield
    1.66%
  • Trailing Div Yield
  • Price/Sales
    0.42
  • Price/Book
    2.23
  • Beta (5-Year)
    0.44
  • Consensus Forward P/E
    10.70
  • Trailing 12-mo Rev

Morningstar's Analysis

Valuation Jan 30, 2025
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Healthcare Services: Medicaid and PBMs Still Under Fire in Updated Regulatory Moves
Author Photo
Julie Utterback, CFA
Senior Equity Analyst
Analyst Note | by Julie Utterback, CFA Updated May 12, 2025

On May 11 and 12, Republicans revealed updated regulatory stances that included plans to lower drug prices and pull back on Medicaid spending by about $715 billion over the next 10 years versus $880 billion expected previously.

Business Strategy and Outlook | by Julie Utterback, CFA Updated Apr 01, 2025

With its roots in health insurance and the late 2018 merger with top-tier pharmacy benefit manager Express Scripts (now called Evernorth), Cigna provides healthcare-related services through customizable programs sold primarily to employers and other insurers. We think its strategy of reducing medical cost growth should resonate well with existing a

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility